Funding
Funding not disclosed
Founders
Product
Problem
Age-related muscle diseases, such as sarcopenia and cachexia, significantly impair quality of life and mobility. Current therapeutic approaches often lack targeted mechanisms to address the underlying molecular pathways that regulate muscle stem cell function and regeneration.
Solution
Animuscure is a research and development company focused on creating novel therapeutics for age-related muscle conditions. The company utilizes a proprietary gene control technology platform to target specific molecular mechanisms that govern muscle stem cell proliferation, maintenance, and differentiation. This approach aims to restore muscle function and combat the progression of degenerative muscle diseases. Animuscure's pipeline includes drug candidates for sarcopenia, cachexia, and other muscle-related disorders, with a strategic focus on developing first-in-class treatments.
Target Audience
Animuscure targets pharmaceutical companies and biotechnology firms seeking to license or co-develop novel therapeutics for muscle-related diseases.
Features
- Proprietary gene control technology for targeted modulation of muscle stem cell function.
- Pipeline candidates for sarcopenia, cachexia, and other age-related muscle diseases.
- Development of novel therapeutics based on identified molecular mechanisms regulating muscle regeneration.
- Focus on first-in-class drug development for muscle-related conditions.
- Research and development efforts also extend to cardiovascular diseases, neurodegenerative disorders, and rare diseases with muscle involvement.
- Active patent portfolio and ongoing patent applications for novel therapeutic compositions and methods.
- Collaboration with academic institutions and research networks to advance drug discovery and development.